DK3082831T3 - Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol - Google Patents

Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol Download PDF

Info

Publication number
DK3082831T3
DK3082831T3 DK14827505.0T DK14827505T DK3082831T3 DK 3082831 T3 DK3082831 T3 DK 3082831T3 DK 14827505 T DK14827505 T DK 14827505T DK 3082831 T3 DK3082831 T3 DK 3082831T3
Authority
DK
Denmark
Prior art keywords
cyclodextrins
diseases
prevention
methyl
concentration
Prior art date
Application number
DK14827505.0T
Other languages
English (en)
Inventor
Marc Salome
Daniel Wils
Xavier Parissaux
Fabrizio Montecucco
François Mach
Original Assignee
Roquette Freres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roquette Freres filed Critical Roquette Freres
Application granted granted Critical
Publication of DK3082831T3 publication Critical patent/DK3082831T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
DK14827505.0T 2013-12-13 2014-12-12 Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol DK3082831T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1362633A FR3014694B1 (fr) 2013-12-13 2013-12-13 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
PCT/FR2014/053309 WO2015087016A1 (fr) 2013-12-13 2014-12-12 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Publications (1)

Publication Number Publication Date
DK3082831T3 true DK3082831T3 (da) 2021-04-12

Family

ID=50424476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14827505.0T DK3082831T3 (da) 2013-12-13 2014-12-12 Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol

Country Status (15)

Country Link
US (2) US10022392B2 (da)
EP (2) EP3082831B1 (da)
JP (2) JP6322289B2 (da)
KR (3) KR20160088874A (da)
CN (2) CN105792833B (da)
AU (2) AU2014363270B2 (da)
BR (1) BR112016013481A2 (da)
CA (2) CA3180528A1 (da)
DK (1) DK3082831T3 (da)
ES (1) ES2859609T3 (da)
FR (1) FR3014694B1 (da)
MX (1) MX2016007658A (da)
PL (1) PL3082831T3 (da)
RU (1) RU2677889C1 (da)
WO (2) WO2015087017A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022841A1 (en) 2012-08-03 2014-02-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
BR112017026287A2 (pt) 2015-06-10 2018-09-18 Vtesse Inc composições de hidroxipropil beta-ciclodextrina e métodos
FR3042501B1 (fr) * 2015-10-16 2017-11-03 Roquette Freres Nouvelles cyclodextrines methylees et leurs procedes de preparation
US20200000840A1 (en) * 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders
US20190224146A1 (en) * 2016-07-08 2019-07-25 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases
KR101906578B1 (ko) * 2017-07-28 2018-10-10 경북대학교 산학협력단 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
EP3687549A4 (en) 2017-09-28 2021-07-14 Asdera LLC USE OF CYCLODEXTRIN IN DISEASES AND DISORDERS WITH PHOSPHOLIPID FAILURE REGULATION
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
CN108342473A (zh) * 2018-04-13 2018-07-31 东华大学 一种用于检测血脂代谢相关基因abcg1甲基化的试剂盒
WO2020002851A1 (fr) * 2018-06-29 2020-01-02 Roquette Freres NOUVELLE HYDROXYPROPYL-β-CYCLODEXTRINE ET SON PROCÉDÉ DE PRÉPARATION
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
WO2020092107A1 (en) 2018-10-29 2020-05-07 Cyclo Therapeutics, Inc. Methods for treating alzheimer's disease
JP2022518147A (ja) 2019-01-03 2022-03-14 アンダードッグ・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
FR3115682B1 (fr) * 2020-11-05 2023-02-24 Roquette Freres Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
WO2023156970A1 (en) * 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265230A (ja) * 1986-05-12 1987-11-18 Kao Corp 高脂血症治療・予防剤
BE1006873A6 (nl) * 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
ES2257824T3 (es) * 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
JP2003514925A (ja) 1999-11-12 2003-04-22 ピサ・アンド・ピサ・エルエルシー ベータ−シクロデキストリン及び関連化合物の部分メチルエーテルの結晶性混合物
AU2001253727A1 (en) * 2000-04-21 2001-11-07 The Trustees Of Columbia University In The City Of New York Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
AUPR178300A0 (en) * 2000-11-29 2000-12-21 Heart Research Institute Ltd., The Cyclodextrins and reversal of atherosclerosis
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
GB0421176D0 (en) 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
US9034846B2 (en) * 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
US7879821B2 (en) * 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives

Also Published As

Publication number Publication date
CA3180528A1 (fr) 2015-06-18
EP3082831B1 (fr) 2021-01-06
FR3014694B1 (fr) 2016-11-11
BR112016013481A2 (pt) 2018-01-16
PL3082831T3 (pl) 2021-06-28
RU2677889C1 (ru) 2019-01-22
CA2930489C (fr) 2023-01-17
CN110123831A (zh) 2019-08-16
EP3082831A1 (fr) 2016-10-26
MX2016007658A (es) 2016-09-26
US11266680B2 (en) 2022-03-08
KR20210072129A (ko) 2021-06-16
EP3581188A1 (fr) 2019-12-18
JP6322289B2 (ja) 2018-05-09
CN105792833B (zh) 2021-06-25
WO2015087017A1 (fr) 2015-06-18
JP2018123153A (ja) 2018-08-09
JP2017500310A (ja) 2017-01-05
US20180207198A1 (en) 2018-07-26
KR102463677B1 (ko) 2022-11-07
AU2014363270A1 (en) 2016-05-19
KR20160088874A (ko) 2016-07-26
US10022392B2 (en) 2018-07-17
CN105792833A (zh) 2016-07-20
AU2014363270B2 (en) 2020-03-12
KR102453643B1 (ko) 2022-10-12
KR20210158867A (ko) 2021-12-31
FR3014694A1 (fr) 2015-06-19
ES2859609T3 (es) 2021-10-04
CA2930489A1 (fr) 2015-06-18
AU2020200500A1 (en) 2020-02-13
US20160361344A1 (en) 2016-12-15
WO2015087016A1 (fr) 2015-06-18
AU2020200500B2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
DK3082831T3 (da) Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2981274T3 (da) Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK2819602T3 (da) Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
DK2707029T3 (da) Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme
DK2925327T3 (da) Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
DK3351630T3 (da) Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer
DK3395353T3 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK2532680T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2903967T3 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og yderligere sygdomme
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
DK3693158T3 (da) Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3508209T3 (da) Sammensætninger med et svækket newcastle sygdoms-virus og fremgangsmåder til anvendelse til behandling af neoplasi
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK3261642T3 (da) Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner